N-Chloraceto-2,4-dichlor-benzylamin | 56978-45-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Chloraceto-2,4-dichlor-benzylamin
• 英文别名: chloro-acetic acid-(2,4-dichloro-benzylamide)；Chlor-essigsaeure-(2,4-dichlor-benzylamid)；2-chloro-N-[(2,4-dichlorophenyl)methyl]-acetamide；N-(2,4-Dichlorobenzyl) chloroacetamide；N-(2,4-dichlorobenzyl)-2-chloroacetamide；2-Chloro-N-(2,4-dichloro-benzyl)-acetamide；2-chloro-N-[(2,4-dichlorophenyl)methyl]acetamide
• CAS: 56978-45-1
• 化学式: C₉H₈Cl₃NO
• mdl: MFCD02316729
• 分子量: 252.528
• InChiKey: PTNHNOLFSVBBBD-UHFFFAOYSA-N

物化性质

• 密度：
  1.403

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Chloraceto-2,4-dichlor-benzylamin 、 p-(2-[(2-hydroxy-3-phenoxypropyl)amino]ethoxy)phenol 在 sodium hydride 作用下， 生成 N-(2,4-Dichloro-benzyl)-2-{4-[2-(2-hydroxy-3-phenoxy-propylamino)-ethoxy]-phenoxy}-acetamide
  参考文献：
  名称：

  Selective .beta.3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates

  摘要：

  The ester methyl [4-[2-[(2-hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetate (8) has been identified as the most interesting member of a series of selective beta-3-adrenergic agonists of brown adipose tissue and thermogenesis in the rat. In vivo it acts mainly via the related acid 10. Potency was generally markedly reduced by placing substituents on the phenyl ring of the phenoxypropanolamine unit of 8; only the 2-fluoro analogue 16 had comparable potency to 8. Other structure-activity relationships are discussed. Further testing of 8 (ICI 198157) has shown that in the rat it stimulates the beta-3-adrenergic receptor in brown adipose tissue at doses lower than those at which it affects beta-1 and beta-2 adrenergic receptors in other tissues. It increases metabolic rate, as judged by an increase in oxygen consumption, and in the genetically obese Zucker rat it causes a reduced rate of weight gain. This class of compound may be useful in the treatment of obesity in man.

  DOI：

  10.1021/jm00088a009
• 作为产物：
  描述：

  N-(2,4-dichloro-benzyl)-phthalimide 在 sodium hydroxide 、 乙醇 、 一水合肼 作用下， 反应 2.0h， 生成 N-Chloraceto-2,4-dichlor-benzylamin
  参考文献：
  名称：

  Preparation of Some New 2-Chloroacetamides

  摘要：

  DOI：

  10.1021/ja01592a061

文献信息

• [EN] COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES<br/>[FR] COMPOSÉS ET PROCÉDÉS PERMETTANT DE TRAITER DES MALADIES DÉPENDANT DE MÉTALLOPROTÉASES À ZINC MATRICIELLES
  申请人：ABSOLUTE SCIENCE INC

  公开号：WO2009045761A1

  公开（公告）日：2009-04-09

  The present invention provides compounds and methods for treating zinc matrix metalloprotease dependent diseases. In certain embodiments, the compounds of the present invention have the following formulas:

  本发明提供了用于治疗锌基质金属蛋白酶依赖性疾病的化合物和方法。在某些实施例中，本发明的化合物具有以下公式：
• An Old Story in the Parallel Synthesis World: An Approach to Hydantoin Libraries
  作者：Andrey V. Bogolubsky、Yurii S. Moroz、Olena Savych、Sergey Pipko、Angelika Konovets、Maxim O. Platonov、Oleksandr V. Vasylchenko、Vasyl V. Hurmach、Oleksandr O. Grygorenko

  DOI：10.1021/acscombsci.7b00163

  日期：2018.1.8

  An approach to the parallel synthesis of hydantoin libraries by reaction of in situ generated 2,2,2-trifluoroethylcarbamates and α-amino esters was developed. To demonstrate utility of the method, a library of 1158 hydantoins designed according to the lead-likeness criteria (MW 200–350, cLogP 1–3) was prepared. The success rate of the method was analyzed as a function of physicochemical parameters

  开发了一种通过原位生成的2,2,2-三氟乙基氨基甲酸酯与α-氨基酯反应平行合成乙内酰脲文库的方法。为了证明该方法的实用性，准备了根据铅样标准（MW 200–350，cLogP 1-3）设计的1158个乙内酰脲文库。分析了该方法的成功率与产品理化参数的关系，发现该方法可以被认为是用于铅导向合成的工具。通过合理设计，使用开发的方法进行平行合成，计算机模拟和体外筛选相结合的方法，发现了一种含乙内酰脲的超微摩尔主要分子，可作为Aurora激酶A抑制剂。
• Lead Optimization and Structure–Activity Relationship Studies on Myeloid Ecotropic Viral Integration Site 1 Inhibitor
  作者：Bengisu Turgutalp、Merve Uslu、Sinem Helvacioglu、Mohammad Charehsaz、Enise Ece Gurdal、Wolfgang Sippl、Fatih Kocabas、Mine Yarim

  DOI：10.1021/acs.jmedchem.1c00972

  日期：2021.10.14

  site (MEIS) inhibitor, MEISi-1, to induce murine and human HSC expansion ex vivo and in vivo. In this work, we performed lead optimization on MEISi-1 by synthesizing 45 novel analogues. Structure–activity relationship studies revealed the significance of a para-methoxy group on ring A and a hydrophobic moiety at the meta position of ring B. Obtained biological data were supported by inhibitor docking and

  我们之前的研究结果报道了骨髓嗜嗜性病毒整合位点 1 (MEIS1) 转录因子在心脏再生和造血干细胞 (HSC) 调节中的关键作用。MEIS1 作为药理抑制背景下的一个有希望的靶点，我们鉴定了一种有效的髓系亲嗜性病毒整合位点 (MEIS) 抑制剂 MEISi-1，可在体外和体内诱导小鼠和人类 HSC 扩增。在这项工作中，我们通过合成 45 种新型类似物对 MEISi-1 进行了先导优化。构效关系研究揭示了环A上的对甲氧基和环B间位的疏水部分的重要性. 获得的生物学数据得到了抑制剂对接和分子动力学模拟研究的支持。11 种化合物被描述为强效抑制剂，证明对 MEIS1 和靶基因Meis1、Hif-1 α 和p21具有更好的抑制作用。其中，4h、4f和4b是最有效的抑制剂。预测的药代动力学特性满足药物相似性标准。此外，化合物对人皮肤成纤维细胞既没有细胞毒性，也没有致突变性。
• [EN] BENZENE DERIVATIVES<br/>[FR] DERIVES DE BENZENE
  申请人：UNIV CARDIFF

  公开号：WO2009125191A1

  公开（公告）日：2009-10-15

  Compounds with the general formula (I): are described wherein R1, R2, R3, R4, R5, Q, T, X, Y and Z are as defined. Compounds according to the invention can display potent inhibition against Hepatitis C Virus (HCV) helicase and potent anti-viral activity against HCV.

  具有一般化学式（I）的化合物被描述，其中R1、R2、R3、R4、R5、Q、T、X、Y和Z如所定义。根据本发明的化合物可以显示出对丙型肝炎病毒（HCV）螺旋酶的强效抑制作用，以及对HCV的强效抗病毒活性。
• Substituted heterocyclic compounds
  申请人：——

  公开号：US20040152890A1

  公开（公告）日：2004-08-05

  Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.

  本发明涉及新型杂环衍生物，可用于治疗各种疾病状态，特别是心血管疾病，如心房和心室心律失常、间歇性跛行、普林兹梅特尔（变异型）心绞痛、稳定和不稳定性心绞痛、运动诱发性心绞痛、充血性心力衰竭和心肌梗塞。该化合物也可用于糖尿病的治疗。